Nabota botox

Bio & Pharma Daewoong wins permission for Nabota in Argentina

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...

Bio & Pharma Korean botox sales gain momentum in US, China

South Korea is ramping up exports of botulinum toxin to the US and China, the world’s two top consumers of the neurotoxin protein, with its pr...

Bio & Pharma Daewoong gets patent of Nabota as migraine drug in US

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it has received a patent from the US Patent and Trademark Office for the use of...

Bio & Pharma Daewoong's Nabota exceeds 600,000 customers in US

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...

Bio & Pharma Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...

Bio & Pharma Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...

Bio & Pharma Korean court rules Daewoong poached Medytox’s botox strain

A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the so...

Bio & Pharma Daewoong Pharma wins permission from Singapore for Nabota

South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin...

Bio & Pharma Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...

Bio & Pharma Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Ja...

Bio & Pharma Hugel accelerates European botox sales with Poland's approval

Hugel Inc., South Korea’s largest maker of botulinum toxin products used to treat overactive muscles and facial wrinkles, has won sales approv...

Bio & Pharma Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukrai...

Bio & Pharma Medytox-Hugel dispute over botox strain intensifies with ITC probe

A legal dispute over a botox strain between South Korean pharmaceutical company Medytox Inc. and its crosstown rival Hugel Inc. has intensified with...

Bio & Pharma Medytox files complaint with ITC against Hugel over botox strain

South Korean pharmaceutical company Medytox Inc. has filed a complaint with the International Trade Commission (ITC) against Hugel Inc., alleging th...

Mergers & Acquisitions GS ups spending to take control of botox maker Hugel

South Korea’s energy-to-retail conglomerate GS Group has increased its spending to become the largest shareholder in Hugel Inc., the country's...

Pharmaceuticals Medytox’s US business outlook dim as contract with AbbVie ends

South Korea’s pharmaceutical company Medytox Inc. has ended a botulinum toxin-related technology transfer contract with AbbVie, clouding its b...

Mergers & Acquisitions Bain Capital sells management rights of Hugel to GS-led group for $1.5 bn

A consortium led by South Korea’s energy-to-construction conglomerate GS Group has acquired the country’s top botox maker Hugel Inc. fro...

M&As Mubadala joins GS-led group to buy Korean botox maker

Abu Dhabi’s sovereign investor Mubadala Investment Co. joined a consortium led by South Korean GS Group to acquire the country’s top bot...

Mergers & Acquisitions Bid for botox maker Hugel to kick off in late July, attracts PEFs

The bid to acquire a controlling stake in Hugel Inc., South Korea’s leading maker of botulinum toxin, more commonly known as botox, from US pr...

Mergers & Acquisitions Samsung looks to acquire bio company, reviews botox maker Hugel

Samsung Group is looking to buy a biopharmaceutical company as the top South Korean business conglomerate is resuming merger and acquisition activit...

Pharmaceuticals GS Group joins race to acquire Korea’s botox maker Hugel

A consortium led by South Korea’s GS Group is in talks to acquire a controlling stake in Hugel Inc., the country’s top maker of botulinu...

Beauty & Cosmetics Korean medical cosmetics firms make big rebound in Q1

South Korean medical cosmetics companies that underwent a tough year in 2020 are posting rejuvenated earning results thanks to s rise in demand in E...